[Challenges of transfusion medicine].
Transfusion medicine has the logic of a therapeutic chain applied to labile blood components and cell therapy products, within a coherent structure, such as the recently created Etablissement français du sang. Faced to the threat of emerging--sometimes hypothetical--transfusion risks, such as the possible transmission of BSE by blood transfusion, the precaution principle requires developing strategies to reduce labile blood components consumption, by strictly defining the framework of blood transfusion prescription and encouraging the search for red blood cell and platelet substitutes. In the field of alternatives to labile blood components, research has however yielded few results. The future of transfusion medicine lies in biotechnology: cell (and gene) therapy will become part of novel therapeutic strategies for the treatment of numerous pathologies in man. Transfusion medicine will have to consider the significant advances achieved over the last few years in the field of multipotent stem cells. Transfusion medicine will thus find its place in the promising field of innovating therapies.
Hervé
P
P
Tiberghien
P
P
D001802:Blood Substitutes / Q000627:therapeutic use; D001803:Blood Transfusion / Q000379:methods / Q000592:standards* / Q000639:trends*; D021821:Communicable Diseases, Emerging / Q000517:prevention & control / Q000635:transmission; D005544:Forecasting; D005602:France; D006801:Humans; D017053:Infection Control / Q000379:methods; D008511:Medicine / Q000458:organization & administration*; D011785:Quality Assurance, Health Care / Q000458:organization & administration; D012307:Risk Factors; D013038:Specialization; D065227:Transfusion Reaction
D001802:Blood Substitutes